Sosne, G., Qiu, P., & Kurpakus-Wheater, M
Overdose Information for Egrifta WR No Information provided Contraindications for Egrifta WR EGRIFTA WR is contraindicated in: Patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma
National Library of Medicine
Lead Researcher Spotlight Professor Frank Ng, PhD Department of Biochemistry and Molecular Biology Monash University, Melbourne, Australia Professor Frank Ng led the pioneering research team that developed AOD-9604 in the 1990s as part of efforts to create a targeted anti-obesity therapeutic derived from human growth hormone
A lot-matched Certificate of Analysis documents identity, purity, and analytical results available for every product, every batch
Increase to 1mg daily and extend the evaluation window to 16 weeks